You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

 

Online download statistics by month:

Online download statistics by month: March 2023 to August 2025

AbstractFullPdf
Mar 202343343779
Apr 202347048093
May 202354555290
Jun 202336036216
Jul 202324124143
Aug 202333533531
Sep 202321621746
Oct 202321621660
Nov 202324925058
Dec 202322022161
Jan 202417917980
Feb 202414915343
Mar 202421321583
Apr 202419219282
May 202416616762
Jun 202418218161
Jul 202417717841
Aug 202413713952
Sep 202415815941
Oct 202416516961
Nov 202417017366
Dec 202414915259
Jan 202518418474
Feb 202511211257
Mar 202513113155
Apr 202514114166
May 202514614653
Jun 202511711742
Jul 2025110
Aug 2025110
Total615562011655